BioMed Valley Discoveries announces participation in NCI-MATCH studies utilizing their first-in-class ERK inhibitor

July 25, 2019

Translational and Clinical Development of Clostridium novyi-NT

May 8-9, 2018

Activity of the ERK1/2 inhibitor Ulixertinib in patients with BRAF and NRAS mutant melanoma

October 18 – 21, 2017

Clostridium novyi-NT: Translational and Clinical Development

July 11 - 12, 2017

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study

June 3, 2017

Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma

April 2, 2017

Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer

November 29 - December 2, 2016

Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors

May 29 - June 2, 2015

The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

April 18 - 22, 2015

Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer

March 2 - 4, 2015

Phase 1 Trial of Image-Guided Oncolysis by Clostridium Novyi-NT Spore Inoculation: Early Technical Insights

January 31, 2015


The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models


Case Report: response to the ER1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma


Paired 18F-Fluorodeoxyglucose (18F-FDG), and 64Cu-Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (64Cu-ATSM) PET Scans in Dogs with Spontaneous Tumors and Evaluation for Hypoxia-Directed Therapy


Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers


Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors


White paper on microbial anti-cancer therapy and prevention


Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine


Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release


Immune response to C. novyi-NT immunotherapy


Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy


Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies


First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Abstract | First Author Interview

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)


Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

Abstract | Commentary

[(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prothetic joint infection.


MRI-Monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model.


Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.


Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.


Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent.


TNF-Alpha blockade is ineffective in animal models of established polycystic kidney disease.


Possible therapeutic effect of trilostaine in rodent models of inflammation and nociception.


Novel anti-inflammatory effects of doxazosin in rodent models of inflammation.


Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis.


Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.


Novel anti-inflammatory effects of repaglinide in rodent models of inflammation.


In vivo effects of immunomodulators in a murine model of Fluorouracil-induced mucositis.


Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.



BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine

September 12, 2022

BioMed Valley Discoveries Announces Poster Presentations on Ulixertinib (BVD-523) at the AACR Annual Meeting 2022

March 22, 2022

BioMed Valley Discoveries’ ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology

July 28, 2020

Bacterial Therapy Tolerable, Shows Early Promise in Patients With Advanced Solid Tumors

September 30, 2018

First-in-class ERK1/2 inhibitor safe, shows early efficacy in patients with advanced solid tumors

December 15, 2017

First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models

October 3, 2017

BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting

May 26, 2017

Bacterial biosurgery shows promise for reducing the size of inoperable tumors

August 13, 2014


The media relations team at the BioMed Valley Discoveries works with local, regional, national, and international media organizations to provide reporters with accurate and timely information about our latest discoveries.

Members of the news media may email inquiries to or contact Joe Chiodo at 724-462-8529.

If you are not a member of the news media or do not have a media-related question, please use the contact form.